JP2019524889A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524889A5
JP2019524889A5 JP2019530368A JP2019530368A JP2019524889A5 JP 2019524889 A5 JP2019524889 A5 JP 2019524889A5 JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019524889 A5 JP2019524889 A5 JP 2019524889A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/047584 external-priority patent/WO2018035449A1/en
Publication of JP2019524889A publication Critical patent/JP2019524889A/ja
Publication of JP2019524889A5 publication Critical patent/JP2019524889A5/ja
Priority to JP2022090843A priority Critical patent/JP2022116294A/ja
Pending legal-status Critical Current

Links

JP2019530368A 2016-08-18 2017-08-18 骨疾患の治療のためのPPARγアゴニスト Pending JP2019524889A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022090843A JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
US62/376,732 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022090843A Division JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Publications (2)

Publication Number Publication Date
JP2019524889A JP2019524889A (ja) 2019-09-05
JP2019524889A5 true JP2019524889A5 (https=) 2020-10-01

Family

ID=61197122

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530368A Pending JP2019524889A (ja) 2016-08-18 2017-08-18 骨疾患の治療のためのPPARγアゴニスト
JP2022090843A Withdrawn JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022090843A Withdrawn JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Country Status (11)

Country Link
US (1) US20190167660A1 (https=)
EP (1) EP3500269A4 (https=)
JP (2) JP2019524889A (https=)
KR (1) KR20190065252A (https=)
CN (1) CN109843292A (https=)
AU (1) AU2017313842A1 (https=)
BR (1) BR112019003133A2 (https=)
CA (1) CA3033971A1 (https=)
EA (1) EA201990513A1 (https=)
SG (2) SG10202101500WA (https=)
WO (1) WO2018035449A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2785317T3 (es) * 2014-10-10 2020-10-06 Liminal Biosciences Ltd Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis

Similar Documents

Publication Publication Date Title
US20240299381A1 (en) Methods of administering elagolix
JP2014139220A5 (https=)
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
Jabbour et al. Bisphosphonates inhibit bone remodeling in the jaw bones of rats and delay healing following tooth extractions
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
JP2015517493A5 (https=)
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2015505564A5 (https=)
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
JP2019507786A5 (https=)
JP2019524889A5 (https=)
JP2016505050A5 (https=)
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
JP2018536638A5 (https=)
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
JP2022116294A (ja) 骨疾患の治療のためのPPARγアゴニスト
JP2019535830A5 (https=)
JP2020505448A5 (https=)
RU2013126798A (ru) Комбинированная терапия дексаметазоном
GEAP202516774A (en) Compactable oral formulations of ibutamoren
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
ZA202201789B (en) Solid oral dosage form comprising naproxen and vitamin b6
EP4469033A4 (en) Pharmaceutical compositions for the treatment of pain